Please login to the form below

Not currently logged in
Email:
Password:

PD-L1 inhibitors

This page shows the latest PD-L1 inhibitors news and features for those working in and with pharma, biotech and healthcare.

Merck puts prostate cancer firmly in Keytruda’s sights

Merck puts prostate cancer firmly in Keytruda’s sights

That combination has made prostate cancer an enticing target for drug developers and in particular those working on cancer immunotherapies, but both PD-1 and PD-L1 checkpoint inhibitors have largely ... The company thinks its phase 3 programme is the

Latest news

More from news
Approximately 1 fully matching, plus 31 partially matching documents found.

Latest Intelligence

  • Immuno-oncology in 2019: the rapid evolution continues Immuno-oncology in 2019: the rapid evolution continues

    In addition to the PD-1 inhibitors Keytruda and Opdivo, there are four PD-L1 inhibitors: Roche’s Tecentriq, AstraZeneca’s Imfinzi, Pfizer and Merck’s Bavencio and Sanofi and ... PD-1/PD-L1 inhibitors: Keytruda is King, but the market is developing

  • The good, the bad and the ugly The good, the bad and the ugly

    Companies are looking to pair their PD-1/PD-L1 checkpoint inhibitors with a variety of other agents to stimulate a more robust anticancer immune response,” says Xuan.

  • European venture funding for the life science sector European venture funding for the life science sector

    is likely to accelerate interest - the sheer number of combination therapies and PD-1/PD-L1 inhibitors could result in a commoditisation of this area that could threaten returns for venture

  • Medius Deal Watch table for March 2015 Medius Deal Watch table for March 2015

    170. Checkpoint Therapeutics / TG. Licence and collaboration. Human anti-PD-L1 and anti-GITR antibody preclinical programmes for  haematological cancers. ... CAR-T and checkpoint inhibitors PD-1 and PD-L1. 110. Transtech / Calithera.

  • Deal Watch table for November 2014 Deal Watch table for November 2014

    PD-L1 and PD-1 CP inhibitors. Co-development and co-marketing alliance. 2, 850. ... FPA008 mAb inhibits (CSF1R) to be combined with nivolumab (PD-1 check-point inhibitor).

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Consulting at McCann Health

We are the strategic consultancy of McCann Health. We combine fresh and creative thinking with scientific and strategic depth...

Latest intelligence

International Childhood Cancer Day 2019
The number of new cases per year is shocking but the journey and the outlooks have vastly improved. We've pulled together an infographic to show just what we mean with...
Immuno-oncology in 2019: the rapid evolution continues
Immunotherapy is pharma’s biggest growth driver – how will it develop in 2019?...
Mixing up Focus Groups
A nice spread of homogeneous participants in a focus groups are often a go to for reliable research outcomes but there's much to be said for mixing it up and...

Infographics